Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
‍
Are you a health professional practicing in the United States?
Yes, take me to Medical Affairs
No, Take me to ParatekPharma.com

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Medical Information Request
Publications & Presentations
Grants & Funding
Product Resources
Disease Education Resources
Medical Affairs
Publications & Presentations

Publications & Presentations

Paratek is committed to enhancing public health through responsible sharing of clinical trial data.

This page contains links to publications and access to congress presentations  related to our products and may contain information regarding approved and non-approved uses, formulations, or treatment regimens. Information provided is not intended to promote any product or indication. Results reported in any single study may not reflect the overall results obtained across the product development.

Please see the Full Prescribing Information available here.

Download a complete bibliography with links to publications and presentations here.

Manuscript Icon
Manuscripts
Poster Icon
Posters

Manuscripts

Explore Paratek's Manuscripts below.

Filters
Clear all
Filter By Category
Clear
Search by Citation
Clear
Areas of Interest
Clear
Clear all
Apply
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters Publications and Manuscripts
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Real World Evidence
Efficacy of omadacycline in the treatment of Legionella pneumonia: a case report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Wang
Citation #
14:1380312
Date
May 2024
Non-Clinical
In vitro activity of omadacycline against clinical isolates of Nocardia
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Pham
Citation #
68(5):e0168623
Date
May 2024
Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Rimal
Citation #
146:102482
Date
May 2024
Review
A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Zurawski
Citation #
usad417
Date
May 2024
Non-Clinical
Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Hu
Citation #
1236:124057
Date
April 2024
Non-Clinical
Antipsychotic Nature of Antibiotics Vancomycin and Omadacycline Combination Ameliorating Stress in a Zebrafish Model
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Raj
Citation #
16(3):e56195
Date
March 2024
Non-Clinical
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Ruiz
Citation #
81: e21-e29
Date
January 2024
Real World Evidence
Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Guillain-Barre Syndrome
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Wang
Citation #
17; 81-87
Date
January 2024
Clinical
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline versus Vancomycin in Healthy Volunteers
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Jo
Citation #
229(1):273-281.
Date
January 2024
Non-Clinical
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model
Resource Type
Manuscript
Areas of Interest
Other
Author Name
Singh
Citation #
Online ahead of print
Date
December 2023
Guideline
CDC Guidelines for the Prevention and Treatment of Anthrax, 2023
Resource Type
Manuscript
Areas of Interest
Biothreats
Author Name
Bower
Citation #
72(6):1-47
Date
November 2023
Real World Evidence
Omadacycline for the treatment of Legionella pneumophila pneumonia caused by drowning: a case report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Lu
Citation #
14(6):481-483
Date
November 2023
Non-Clinical
Compatibility of Omadacycline With Select Parenteral Products in Simulated Y-Site Administration
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Butler
Citation #
S0149-2918(23)00349-1
Date
November 2023
Real World Evidence
Omadacycline use in a traveler with severe Legionella pneumonia
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Wang
Citation #
56:102654
Date
October 2023
Real World Evidence
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
El Ghali
Citation #
67(10):e0082423
Date
October 2023
Non-Clinical
Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Jahanbakhsh
Citation #
5(5):dlad104
Date
October 2023
Real World Evidence
Case Report: Omadacycline in the treatment of macrolide unresponsive Mycoplasma pneumoniae pneumonia in an adolescent patient
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Xu
Citation #
13:1244398
Date
September 2023
Real World Evidence
Case Report: Omadacycline in the treatment of macrolide unresponsive Mycoplasma pneumoniae pneumonia in an adolescent patient
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Xu
Citation #
13:1244398
Date
September 2023
Clinical
Community-acquired Pneumonia
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
File
Citation #
389:632-41
Date
August 2023
Clinical
Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Rodriguez
Citation #
online ahead of print
Date
July 2023
Real World Evidence
Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Mingora
Citation #
10(7):ofad335
Date
July 2023
Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Skinner
Citation #
78(7):1779-1784
Date
July 2023
Microbiology
In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Li
Citation #
50(7):604-609
Date
July 2023
Show More Resources
No results found.
There are no results with this criteria. Try changing your search.

Posters

Explore Paratek's Publications below.

2025
CHEST 2025
accordio_arrow
CHEST 2025
IDWeek 2025
accordio_arrow
IDWeek 2025
MAD-ID 2025
accordio_arrow
MAD-ID 2025
ATS 2025
accordio_arrow
ATS 2025
SAWC 2025
accordio_arrow
SAWC 2025
ESCMID Global
accordio_arrow
ESCMID Global 2025
2024
IDWeek 2024
accordio_arrow
IDWeek 2024
MHSRS
accordio_arrow
MHSRS 2024
ASM Microbe
accordio_arrow
ASM Microbe 2024
ESCMID Global (formally ECCMID)
accordio_arrow
ESCMID Global (formally ECCMID)
Texas Medical Center AMR & Stewardship
accordio_arrow
Texas Medical Center AMR & Stewardship
2023
ASM Microbe
accordio_arrow
ASM Microbe 2023
IDWeek
accordio_arrow
IDWeek 2023
ECCMID
accordio_arrow
ECCMID 2023
2022
IDWeek
accordio_arrow
IDWeek 2022
MHSRS
accordio_arrow
MHSRS 2022
ASM-Microbe
accordio_arrow
ASM-Microbe 2022
ID Week 2021
accordio_arrow
ID Week 2021
2020
IDWEEK
accordio_arrow
IDWEEK 2020
2019
ASM-ESCMID
accordio_arrow
ASM-ESCMID 2019
IDWEEK
accordio_arrow
IDWEEK 2019
View All
Omadacycline in Vitro Activity Against Bacillus anthracis
Efficacy of Drug Regimens Containing Omadacycline in a Murine Model of Mycobacterium avium Chronic Lung Infection
Microbiological Outcomes of Oral Omadacycline Treatment in Adults with Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc): Results from a Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Trial
Omadacycline outcomes in community-acquired bacterial pneumonia: pooled efficacy and safety from the Phase 3 OPTIC and OPTIC-2 trials.
Omadacycline was Shown to Preserve the Microbiome in a Murine Model of Post-Influenza MRSA Pneumonia
Health-related quality-of-life outcomes in OPTIC-2: A randomized, controlled, Phase 3b trial of omadacycline vs. moxifloxacin in community-acquired bacterial pneumonia
In Vitro Activity of Omadacycline and Comparator Agents Against Periodontal Pathogens
Susceptibility of Omadacycline in Bone and Joint Infections: Pathogen Susceptibility and Regimen Decisions from an Ongoing Randomized Controlled Trial
Pooled Microbiological Outcomes from the Phase 3, Randomized OPTIC and OPTIC-2 Trials of Omadacycline vs Moxifloxacin in Community-Acquired Bacterial Pneumonia
Real-world Efficacy and Safety of Omadacycline in Immunocompromised Patients
Tigecycline as a Surrogate for Omadacycline Susceptibility in Enterococcus faecalis and Enterococcus faecium
Omadacycline for Community-acquired Bacterial Pneumonia (OPTIC-2): A Phase 3b Randomized, Double-blind, Multicenter, Controlled, Noninferiority Trial
A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adults With Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) Caused by Mycobacterium Abscessus
Prescription Patterns among Outpatients with Antibiotic Failure/Intolerance in the Treatment ​ of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A 2020 to 2022 Retrospective Cohort Study​
Omadacycline for Skin and Soft Tissue Infections: A Multicenter Retrospective Analysis of Efficacy and Safety in Real-World Clinical Practice
Omadacycline for Skin and Soft Tissue Infections: A Multicenter Retrospective Analysis of Efficacy and Safety in Real-World Clinical Practice
Clinical Efficacy and Safety of Omadacycline in the Treatment of Enterococcal Infections
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023)
Omadacycline demonstrated efficacy as both therapeutic treatment and post-exposure prophylaxis against inhalation anthrax and pneumonic plague in cynomolgus macaques
Clinical and microbiological outcomes of omadacycline for pulmonary Mycobacterium abscessus complex
Evaluation of Fecal Pharmacokinetics and Metagenomic Changes Following the Administration of Intravenous Omadacycline to Healthy Subjects
Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) among Outpatient and Urgent Care Visits
In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020
Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results From an Open-Label, Non-Inferiority, Randomized Controlled Trial
Omadacycline is Active Against Multidrug Resistant Bacillus Anthracis Strains Resistant to Tetracyclines
In Vitro Interaction of Omadacycline in Combination with Melatonin against Carbapenemase producing Klebsiella pneumoniae
Evaluation of Omadacycline Treatment for Osteomyelitis
Omadacycline alone and in combination as a treatment option for Mycobacterium avium infections
Minimum inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline
Real-World Outpatient Use of Omadacycline for Bone and Joint Infections
Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections
Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)
Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review
Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in New Zealand White Rabbits
Omadacycline Efficacy in a Post-Exposure Prophylaxis Mouse Model of Inhalational Anthrax Caused by Ciprofloxacin-Resistant Bacillus anthracis
In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programmme
Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
Preclinical evaluation of omadacycline for potential as a drug to treat Acinetobacter baumannii and Klebsiella pneumoniae infections in combat wounds
In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars
Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease
Omadacycline in Vitro Activity Against Bacillus Anthracis
Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria
No items found.
No items found.
No items found.

Contact Us

If you would like to speak to a Paratek Medical Information Professional please call 1-833-PARATEK (1-833-727-2835) or email medinfo@paratekpharma.com. Otherwise please see below.

Medical Information
If you would like to speak to a Paratek Medical Information Professional or speak with a Field Medical professional:
‍
Call: 1-833-PARATEK (1-833-727-2835)
Email: medinfo@paratekpharma.com

 Please include the following in your request:
- Your name
- Specialty/affiliation
- Professional designation
Report a Product Complaint
To report a Product Quality Complaint for a Paratek product:

Call: 1-833-PARATEK (1-833-727-2835)
Email: drugsafety@propharmagroup.com
Report an Adverse Event
To report an Adverse Event for a Paratek product: 

Call: 1-833-PARATEK (1-833-727-2835)
Email: drugsafety@propharmagroup.com

You can also contact the FDA:

Call:  1-800-FDA-1088
Email: www.fda.gov/medwatch

Privacy Policy | Terms and Conditions | Social Media Guidelines | Compliance Program | Expanded Access Policy

© 2024 Paratek Pharmaceuticals, Inc. All rights reserved. PARATEK® and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA® and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc.

US-COR-0050-01 06/24